Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $9.2300 (-0.86%) ($9.0500 - $9.7500) on Fri. Jul. 10, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 16.91% (three month average) | RSI | 37 | Latest Price | $9.2300(-0.86%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.2% a day on average for past five trading days. | Weekly Trend | ADAP declines -1.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) XBI(23%) IWC(22%) XLRE(22%) DRIV(21%) IBB(19%) | Factors Impacting ADAP price | ADAP will decline at least -8.455% in a week (0% probabilities). TLT(-12%) BNDX(-10%) VXX(-9%) TIP(-9%) BND(-9%) | | | | | Relative Volatility | | | | Market Trend Strength | -8.455% (StdDev 16.91%) | Hourly BBV | 0 () | Intraday Trend | -0.6% | | | |
|
1 - 5 Day Possible Target | $2.08(-77.46%) | Resistance Level | $9.72 | 5 Day Moving Average | $9.42(-2.02%) | 10 Day Moving Average | $9.56(-3.45%) | 20 Day Moving Average | $9.72(-5.04%) | To recent high | -23.7% | To recent low | 78.5% | Market Cap | $1.427b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |